Bristol Joins The Ranks: Firm Bags Pargluva Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck, AstraZeneca and Roche have already stepped out of the dual PPAR development arena.
You may also be interested in...
Chart: PDUFA Drug Safety Plan: CDER's Epidemiology Studies
PDUFA Drug Safety Plan: CDER's Epidemiology Studies
Avandia Safety Under The Microscope
Cardiovascular risks identified in a meta-analysis by Steven Nissen prompt immediate announcements of an advisory committee meeting and congressional investigations.
Avandia Safety Under The Microscope
Cardiovascular risks identified in a meta-analysis by Steven Nissen prompt immediate announcements of an advisory committee meeting and congressional investigations.